Ocugen Provides Business Update with Second Quarter 2023 Fin

Conference Call and Webcast Tomorrow at 8:30 a.m. ET • Investigational New Drug Applications Cleared for Novel Gene Therapies for Geographic Atrophy Secondary to AMD and for Stargardt Disease ...

Related Keywords

, Shankar Musunuri , Exchange Commission , Head Of Communications , Ocugen Inc , Linkedin , Twitter , Association For Research , Conference Call , Webcast Tomorrow , Investigational New Drug , Applications Cleared , Novel Gene Therapies , Geographic Atrophy Secondary , Study Results Update Expected This , Chief Executive Officer , Geographic Atrophy , Mucosal Vaccine Platform , Private Securities Litigation Reform Act , Markets ,